Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The approved product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme's BRIDION Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
The company said it has commercially launched the product in the U.S. on the first day of approval through its marketing partner.
According to IQVIA, Sugammadex Injection recorded U.S. sales of about $1.6 billion during the 12 months ended April 2026, highlighting a sizeable market opportunity.
Gland Pharma is a Hyderabad-based pharmaceutical company focused on generic injectables and ophthalmics. It operates in more than 60 countries under a business-to-business model and offers a broad portfolio of sterile injectable products, including vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic solutions.
On a consolidated basis, Gland Pharma's net profit surged 96.57% to Rs 366.68 crore while net sales rose 22.31% to Rs 1742.79 crore in Q4 March 2026 over Q4 March 2025.
Gland Pharma (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BRIDION® Injection of Merck Sharp & Dohme LLC.
The Product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2510.4, up 1.92% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.16% on the day, quoting at 24468.6. The Sensex is at 78452.78, up 0.21%. Gland Pharma Ltd has gained around 11.68% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 6.86% in last one month and is currently quoting at 25866.25, down 0.24% on the day. The volume in the stock stood at 6.18 lakh shares today, compared to the daily average of 8.44 lakh shares in last one month.
The PE of the stock is 30.83 based on TTM earnings ending March 26.
Consumer durables shares extend losses for a third consecutive session.
At 10:25 IST, the barometer index, the S&P BSE Sensex declined 832.12 points or 1.10% to 74,413.21 The Nifty 50 index dropped 261.20 points or 1.10% to 23,382.30.
The broader market underperformed the frontline indices. The BSE 150 MidCap Index tumbled 1.66% and the BSE 250 SmallCap Index dropped 2.57%.
The market breadth was negative. On the BSE, 764 shares rose and 3,102 shares fell. A total of 204 shares were unchanged.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 96.2300 compared with its previous close of 95.8100. It also touched an all-time intraday low of 96.25 today.
In the commodities market, Brent crude for July 2026 settlement rose $1.83 cents or 1.67% to $111.09 a barrel.
Earnings to Watch:
Indian Oil Corporation(down 2.42%), Afcons Infrastructure(down 6.87%), Ola Electric Mobility(down 3.17%), Apollo Micro Systems(down 2.16%), Indraprastha Gas(down 1.22%), JSW Cement(down 1.95%), Puravankara(down 1.90%), Sun Pharma Advanced Research Company(down 2.26%), Strides Pharma Science(down 1.81%), Baazar Style Retail (down 5.01%) and Zydus Wellness(down 2.94%) will announce their quarterly earnings today.
Buzzing Index:
The Nifty consumer durables index tumbled 3.34% to 34,366.50. The index fell 3.42% in the two consecutive trading sessions.
Amber Enterprises India (down 13.68%), PG Electroplast (down 5.56%), Blue Star (down 3.8%), Kalyan Jewellers India (down 3.41%), Crompton Greaves Consumer Electricals (down 2.86%), LG Electronics India (down 2.84%), Dixon Technologies (India) (down 2.4%), Havells India (down 2.38%), Bata India (down 2.27%) and Titan Company (down 2.05%) tumbled.
Stocks in Spotlight:
Gland Pharma surged 12.47% after the pharma company has reported 96.62% increase in consolidated net profit to Rs 366.7 crore on a 22.31% rise in net sales to Rs 1,742.80 crore in Q4 FY26 over Q4 FY25.
NCC slipped 5.22% after the company reported an 18.8% drop in consolidated net profit to Rs 206.02 crore in Q4 FY26, compared to Rs 253.82 crore recorded in Q4 FY25.
Gland Pharma Ltd, Premier Energies Ltd, Cohance Lifesciences Ltd, Shree Cement Ltd are among the other stocks to see a surge in volumes on BSE today, 18 May 2026.
J K Cements Ltd registered volume of 58311 shares by 10:46 IST on BSE, a 12.2 fold spurt over two-week average daily volume of 4779 shares. The stock slipped 1.11% to Rs.5,400.00. Volumes stood at 2233 shares in the last session.
Gland Pharma Ltd clocked volume of 1.95 lakh shares by 10:46 IST on BSE, a 8.25 times surge over two-week average daily volume of 23679 shares. The stock gained 15.41% to Rs.2,154.75. Volumes stood at 4285 shares in the last session.
Premier Energies Ltd clocked volume of 2.98 lakh shares by 10:46 IST on BSE, a 6.61 times surge over two-week average daily volume of 45115 shares. The stock gained 0.92% to Rs.990.40. Volumes stood at 27610 shares in the last session.
Cohance Lifesciences Ltd witnessed volume of 21.15 lakh shares by 10:46 IST on BSE, a 5.62 times surge over two-week average daily volume of 3.76 lakh shares. The stock dropped 1.69% to Rs.416.05. Volumes stood at 1.19 lakh shares in the last session.
Shree Cement Ltd notched up volume of 5187 shares by 10:46 IST on BSE, a 5.58 fold spurt over two-week average daily volume of 930 shares. The stock slipped 2.48% to Rs.24,348.85. Volumes stood at 539 shares in the last session.
Profit before tax stood at Rs 505.79 crore in Q4 FY26, up by 75.42% from Rs 288.33 crore recorded in Q4 FY25.
Consolidated EBITDA stood at Rs 513 crore in Q4 March 2026, registering the growth of 48% YoY with EBITDA margin of 29%.
R&D expenses stood at Rs 50.6 crore in Q4 FY26, accounting for 4% of base business revenue, and were primarily directed toward complex product development and filings. During the quarter, the company launched five molecules in the US, including Dalbavancin and Brimonidine, taking total US launches in FY26 to 31 products.
On the regulatory front, eight ANDA filings were made and 11 approvals were received in Q4 FY26, while FY26 saw 24 filings and 28 approvals, taking cumulative US ANDA filings to 388 (337 approved and 51 pending). The in-house complex pipeline continues to strengthen with six products already launched and three awaiting approval, with complex injectables expected to remain a key long-term growth driver.
Under co-development partnerships, 15 products are in development, including seven 505(b)(2) and eight ANDAs, with commercialization expected from FY28. The company also advanced its Ready-to-Use (RTU) bag portfolio with 21 filings, 18 approvals, and 11 products under development, addressing an estimated US market opportunity of $634 million.
In the GLP-1 and insulin analog segment, the company launched Liraglutide in the US, with pen/cartridge capacity at 140 million units per annum. Additionally, a new CDMO contract was signed for a complex nano drug delivery system-based injectable in oncology.
Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses including Cenexi. The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing costefficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.”
The board has recommended a final dividend of Rs 20 per equity share of face value Rs 1 each (2000%) for FY26. If approved, the dividend will be paid within 30 days from the date of the 48th Annual General Meeting. The record date for determining eligible shareholders has been fixed as Tuesday, August 11, 2026.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
Great Eastern Shipping Company Ltd, Raymond Ltd, Arvind Ltd and Shipping Corporation of India Ltd are among the other gainers in the BSE's 'A' group today, 18 May 2026.
Gland Pharma Ltd surged 13.81% to Rs 2124.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 2.25 lakh shares were traded on the counter so far as against the average daily volumes of 14321 shares in the past one month.
Great Eastern Shipping Company Ltd soared 10.15% to Rs 1687.5. The stock was the second biggest gainer in 'A' group. On the BSE, 8.78 lakh shares were traded on the counter so far as against the average daily volumes of 1.1 lakh shares in the past one month.
Raymond Ltd spiked 7.44% to Rs 488.6. The stock was the third biggest gainer in 'A' group. On the BSE, 2.18 lakh shares were traded on the counter so far as against the average daily volumes of 74378 shares in the past one month.
Arvind Ltd exploded 5.45% to Rs 475.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.06 lakh shares were traded on the counter so far as against the average daily volumes of 69959 shares in the past one month.
Shipping Corporation of India Ltd spurt 4.86% to Rs 347.15. The stock was the fifth biggest gainer in 'A' group. On the BSE, 10.18 lakh shares were traded on the counter so far as against the average daily volumes of 10.2 lakh shares in the past one month.